Developer docs
API playgroundTry for free, no card

Search company profiles

CACNA1A Foundation

Full company profile

uuid002j8lj

Namestring
CACNA1A Foundation
Legal namestring
CACNA1A Foundation, Inc.
Websiteurl
cacna1a.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

CACNA1A Foundation is a parent-led 501(c)(3) non-profit organization, headquartered in Norwalk, Connecticut, that funds research, builds community, and advocates for patients and families affected by CACNA1A-related genetic disorders, which include ataxia, epilepsy, hemiplegic migraines, developmental delays, and cerebellar atrophy. The foundation was founded in 2019 and operates as an all-volunteer organization with no paid staff, led by President and Co-Founder Lisa Manaster with a Science Engagement Director (Dr. Pangkong Fox) and a Board of Directors supported by a Scientific & Medical Advisory Board and a Global Ambassadors program.

Its core operational assets are research-enabling platforms rather than commercial products: the CACNA1A Natural History Study, a retrospective and prospective longitudinal patient registry operated in partnership with the Chung Lab at Columbia University / Boston Children's Hospital using REDCap; and the RARE-X Data Collection Program, a patient-owned structured data sharing platform powered by the Broad Institute of MIT and Harvard. The foundation also convenes an annual research roundtable at NINDS/NIH (attendance growing from 37 experts in 2022 to 70 in 2025), runs an annual Family & Scientific Conference, and publishes the "Clarify CACNA1A" blog and monthly newsletter.

The foundation generates no commercial revenue. It is funded through individual donations and community fundraisers (including an annual Run/Walk/Roll), and through grants such as the 3-year Rare As One capacity-building grant awarded by the Chan Zuckerberg Initiative in 2021. In 2020 it raised approximately $200,000 and set a $300,000 goal for 2021. Recent milestones include the first CACNA1A Disease Concept Model Study (American Epilepsy Society, 2024), a new ICD-10 code QA0.0102 for CACNA1A-related Neurodevelopmental Disorder effective October 1, 2025, the launch of the first CACNA1A multidisciplinary clinic in 2025, and an FDA Patient Listening Session in January 2026. The foundation holds a Charity Navigator 4-star rating and a Candid/GuideStar Platinum Seal of Transparency.

Short descriptiontext

CACNA1A Foundation is a parent-led 501(c)(3) non-profit that funds research, runs a longitudinal Natural History Study and RARE-X patient data program, and supports a global community of patients and families affected by CACNA1A-related genetic disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorwalk, United States
HQ citystring
Norwalk
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, patient registry services, natural history study, research grant funding, patient community support
Industry3 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJALAB
Health Research Funding Agencies (Public/Quasi-Public)
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration
SECONDARYHLAJALAF
Community Health & Prevention Program Funding
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services81321
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Rare Disease Patient Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Fundraising
TypeGrants Donations
Description

The foundation relies on charitable donations from individuals, families, and supporters. In 2020, the foundation raised nearly $200,000 and set a goal of $300,000 for 2021. Fundraising efforts include community events such as the CACNA1A Run/Walk/Roll.

cacna1a.org
2Research and Operating Grants
TypeProfessional Services
Description

The foundation receives grants including a 3-year Rare As One (RAO) grant from the Chan Zuckerberg Initiative (CZI) received in 2021 to build organizational capacity. Operating grants are also sought to support foundation activities.

cacna1a.org
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

CACNA1A Foundation is a parent-led 501(c)(3) non-profit that funds life-changing research and provides free educational, community, and research-engagement services for individuals and families affected by CACNA1A-related disorders. Its core offerings include the CACNA1A Natural History Study (with the Chung Lab at Columbia University), the RARE-X Data Collection Program, a Research Grant Program, an annual Family & Scientific Conference, a webinar series, a contact registry, and an extensive library of clinician and family resources.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • New ICD-10 code QA0.0102 obtained for CACNA1A-related Neurodevelopmental Disorder effective October 2025
+3 more records
Product overview1 text field

CACNA1A Foundation is a parent-led 501(c)(3) non-profit organization dedicated to creating awareness and finding a cure for CACNA1A genetic variants. The foundation does not offer a commercial product or software platform. Its primary offerings consist of educational resources, research coordination services, and community support programs for individuals and families affected by CACNA1A-related disorders. Key service offerings include: a comprehensive website providing information about CACNA1A-related disorders; a Natural History Study conducted in partnership with the Chung Lab at Columbia University to collect patient data for research; the RARE-X Data Collection Program for patient-owned data sharing; an annual Family & Scientific Conference; a blog (Clarify CACNA1A) with research updates and community stories; educational webinars; clinician and patient resources; and a contact registry for community engagement. The foundation also coordinates research grants, maintains a global research network, and advocates for the CACNA1A community.

Product and service8 records
1CACNA1A Natural History Study
CategoryPatient Registry / Natural History Study
2RARE-X Data Collection Program (CACNA1A)
CategoryPatient Data Platform
3CACNA1A Research Grant Program
CategoryResearch Funding
4CACNA1A Family & Scientific Conference
CategoryConference / Community Event
5CACNA1A Contact Registry
CategoryCommunity Registry
6CACNA1A Educational Webinar Series
CategoryEducational Programming
7CACNA1A Research Roundtable
CategoryScientific Convening
8CACNA1A Disease Concept Model Study
CategoryPatient-Reported Outcomes Research
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

COMBINEDbrain is a non-profit consortium of 25 patient-advocacy foundations representing rare genetic neurodevelopmental disorders. The foundation joined as a member in April 2021 to pool efforts, studies and data, and accelerate clinical trial readiness. The consortium de-risks therapeutic development by grouping disorders with similar symptoms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

RARE-X is a 501(c)(3) nonprofit data-sharing platform powered by the Broad Institute of MIT and Harvard. The foundation partnered with RARE-X to build a Data Collection Program for the CACNA1A community to accelerate discovery of treatments through patient-owned, structured data collection.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-01
Description

NINDS, part of the NIH, is the largest funding body for scientific research in the US. The foundation hosts annual Research Roundtables at NINDS facilities, with NINDS grant program managers participating in working groups focused on natural history, variant classification, and preclinical to clinical pathways.

4Chung Lab at Columbia University / Boston Children's Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Wendy Chung leads the CACNA1A Natural History Study. In July 2023, Dr. Chung joined Boston Children's Hospital as Chief of Pediatrics while maintaining her role leading clinical research at the Simons Foundation. She directs NIH-funded research programs and has authored over 400 peer-reviewed papers. The foundation partnered with her lab to conduct comprehensive natural history data collection.

cacna1a.org
Strategic tierMinorTypeGTM or Marketing Partner
Description

Reference resource for seizure monitoring devices. The Danny Did Foundation provides grants for seizure monitoring devices, which are recommended safety equipment for CACNA1A patients with epilepsy.

6NAPA Center
Strategic tierMinorTypeGTM or Marketing Partner
Description

NAPA Center is a pediatric therapy center with five US locations (L.A., Denver, Boston, Austin, Chicago) and two in Australia. They offer free online resources and tips for feeding therapies relevant to CACNA1A families dealing with feeding difficulties due to autism, sensory processing deficits, and motor impairments.

cacna1a.org
Strategic tierMinorTypeGTM or Marketing Partner
Description

DRLC provides litigation support and advocacy resources for CACNA1A families navigating disability rights issues including school accommodations, healthcare access, and insurance matters. Christopher Knauf serves as Director of Litigation contributing educational content.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Wendy Chung serves as Director of Clinical Research at the Simons Foundation, which runs Simons Searchlight study for neurogenetic conditions. Simons Searchlight serves as a model for data collection approaches.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Ingo Helbig from CHOP participated in the FDA Patient Listening Session in January 2026. CHOP researchers collaborate on research initiatives and provide clinical expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Pangkong Fox serves as Science Engagement Director for the foundation and led the CACNA1A Disease Concept Model Study with COMBINEDBrain, identifying key symptoms impacting quality of life.

Strategic tierCoreTypeTechnology or Integration
Description

The Broad Institute powers the RARE-X data collection platform used by the foundation. It supports patients in data collection and structuring, clinicians in accelerating diagnosis, and researchers with data needed for breakthrough treatments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

501(c)(3) data-sharing platform powered by the Broad Institute that helps rare disease communities (including CACNA1A) collect, structure, and share patient-owned data. A direct operational and strategic partner of the foundation and a model peer for patient-driven research infrastructure.

TypeDirect peer
Description

Parent-led 501(c)(3) focused on STXBP1-related disorders, a related rare genetic neurodevelopmental condition. Operates a similar model: natural history study, family registry, research grants, and clinician education. COMBINEDbrain co-member with overlapping scientific network.

TypeDirect peer
Description

Patient-advocacy foundation for SYNGAP1-related neurodevelopmental disorder. Similar parent-led, all-volunteer DNA-driven model with research grants, registry, and FDA engagement; overlapping scientific advisory networks and COMBINEDbrain consortium participation.

TypeBroad incumbent
Description

Largest US umbrella organization for rare disease patient advocacy. Does not specialize in CACNA1A but provides policy advocacy, research grants, and registry infrastructure that smaller single-disease foundations leverage; a natural policy/umbrella peer.

TypeBroad incumbent
Description

DC-based rare disease policy and advocacy nonprofit focused on federal funding, FDA engagement, and newborn screening. Operates one level above single-disease foundations, including CACNA1A, shaping the regulatory environment they depend on.

TypeDirect peer
Description

Family-driven foundation supporting research and awareness for SCN2A-related disorders, another ion-channel mutation with overlapping ataxia/epilepsy phenotypes. Operates with a similar small-staff, parent-led, research-grant-funding model.

TypeEmerging player
Description

Research program of the Simons Foundation collecting phenotypic and genetic data for rare neurogenetic conditions (including some overlapping channelopathies). Functions as both a partner and a competing/complementary registry model for CACNA1A natural history efforts.

TypeDirect peer
Description

Non-profit consortium of 25 patient-advocacy foundations for rare genetic neurodevelopmental disorders. CACNA1A Foundation is a member; the organizations share clinical-trial readiness infrastructure, natural history approaches, and Disease Concept Model studies for overlapping indications.

TypeDirect peer
Description

Patient-advocacy foundation for Dravet syndrome (a rare genetic epilepsy). Runs research grant programs, family conferences, and FDA engagement. A more mature peer showing the path from parent-led foundation to clinical-trial pipeline for a CACNA1A-overlapping channelopathy.

TypeOthers
Description

CZI's Rare As One program funds a network of rare disease patient-led foundations (including CACNA1A Foundation) to build organizational capacity and accelerate research. Less a peer and more the foundation's primary philanthropic sponsor and peer cohort network.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CACNA1A Foundation

Rare Disease Patient Advocacycacna1a.org

CACNA1A Foundation is a parent-led 501(c)(3) non-profit that funds research, runs a longitudinal Natural History Study and RARE-X patient data program, and supports a global community of patients and families affected by CACNA1A-related genetic disorders.

What CACNA1A Foundation does

CACNA1A Foundation is a parent-led 501(c)(3) non-profit organization, headquartered in Norwalk, Connecticut, that funds research, builds community, and advocates for patients and families affected by CACNA1A-related genetic disorders, which include ataxia, epilepsy, hemiplegic migraines, developmental delays, and cerebellar atrophy. The foundation was founded in 2019 and operates as an all-volunteer organization with no paid staff, led by President and Co-Founder Lisa Manaster with a Science Engagement Director (Dr. Pangkong Fox) and a Board of Directors supported by a Scientific & Medical Advisory Board and a Global Ambassadors program.

Its core operational assets are research-enabling platforms rather than commercial products: the CACNA1A Natural History Study, a retrospective and prospective longitudinal patient registry operated in partnership with the Chung Lab at Columbia University / Boston Children's Hospital using REDCap; and the RARE-X Data Collection Program, a patient-owned structured data sharing platform powered by the Broad Institute of MIT and Harvard. The foundation also convenes an annual research roundtable at NINDS/NIH (attendance growing from 37 experts in 2022 to 70 in 2025), runs an annual Family & Scientific Conference, and publishes the "Clarify CACNA1A" blog and monthly newsletter.

The foundation generates no commercial revenue. It is funded through individual donations and community fundraisers (including an annual Run/Walk/Roll), and through grants such as the 3-year Rare As One capacity-building grant awarded by the Chan Zuckerberg Initiative in 2021. In 2020 it raised approximately $200,000 and set a $300,000 goal for 2021. Recent milestones include the first CACNA1A Disease Concept Model Study (American Epilepsy Society, 2024), a new ICD-10 code QA0.0102 for CACNA1A-related Neurodevelopmental Disorder effective October 1, 2025, the launch of the first CACNA1A multidisciplinary clinic in 2025, and an FDA Patient Listening Session in January 2026. The foundation holds a Charity Navigator 4-star rating and a Candid/GuideStar Platinum Seal of Transparency.

CACNA1A Foundation firmographics

Firmographics
Name
CACNA1A Foundation
Legal name
CACNA1A Foundation, Inc.
Website
https://cacna1a.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
CACNA1A Foundation is a parent-led 501(c)(3) non-profit that funds research, runs a longitudinal Natural History Study and RARE-X patient data program, and supports a global community of patients and families affected by CACNA1A-related genetic disorders.
Ownership category
akta.pro rank

CACNA1A Foundation industry classification

Industry
Product category
Rare Disease Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJALAB
Health Research Funding Agencies (Public/Quasi-Public)
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration
SECONDARYHLAJALAF
Community Health & Prevention Program Funding
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration

Keywords

  • Rare disease advocacy
  • Patient registry services
  • Natural history study
  • Research grant funding
  • Patient community support

Where CACNA1A Foundation is headquartered

Location

Headquarters

HQ city
Norwalk
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CACNA1A Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Donations and Fundraising: The foundation relies on charitable donations from individuals, families, and supporters. In 2020, the foundation raised nearly $200,000 and set a goal of $300,000 for 2021. Fundraising efforts include community events such as the CACNA1A Run/Walk/Roll.
  2. Research and Operating Grants: The foundation receives grants including a 3-year Rare As One (RAO) grant from the Chan Zuckerberg Initiative (CZI) received in 2021 to build organizational capacity. Operating grants are also sought to support foundation activities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

CACNA1A Foundation product offering

Product offering

Core offering

CACNA1A Foundation is a parent-led 501(c)(3) non-profit that funds life-changing research and provides free educational, community, and research-engagement services for individuals and families affected by CACNA1A-related disorders. Its core offerings include the CACNA1A Natural History Study (with the Chung Lab at Columbia University), the RARE-X Data Collection Program, a Research Grant Program, an annual Family & Scientific Conference, a webinar series, a contact registry, and an extensive library of clinician and family resources.

Product overview

CACNA1A Foundation is a parent-led 501(c)(3) non-profit organization dedicated to creating awareness and finding a cure for CACNA1A genetic variants. The foundation does not offer a commercial product or software platform. Its primary offerings consist of educational resources, research coordination services, and community support programs for individuals and families affected by CACNA1A-related disorders. Key service offerings include: a comprehensive website providing information about CACNA1A-related disorders; a Natural History Study conducted in partnership with the Chung Lab at Columbia University to collect patient data for research; the RARE-X Data Collection Program for patient-owned data sharing; an annual Family & Scientific Conference; a blog (Clarify CACNA1A) with research updates and community stories; educational webinars; clinician and patient resources; and a contact registry for community engagement. The foundation also coordinates research grants, maintains a global research network, and advocates for the CACNA1A community.

Differentiator

Problem solved

Functional benefit

Products and services

  • CACNA1A Natural History Study
  • RARE-X Data Collection Program (CACNA1A)
  • CACNA1A Research Grant Program
  • CACNA1A Family & Scientific Conference
  • CACNA1A Contact Registry
  • CACNA1A Educational Webinar Series
  • CACNA1A Research Roundtable
  • CACNA1A Disease Concept Model Study

Quantifiable outcome

  • New ICD-10 code QA0.0102 obtained for CACNA1A-related Neurodevelopmental Disorder effective October 2025
  • +3 more outcomes

Companies that use CACNA1A Foundation

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

CACNA1A Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

CACNA1A Foundation partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • COMBINEDbraincoreStrategic or Co-development Partner · 1 April 2021COMBINEDbrain is a non-profit consortium of 25 patient-advocacy foundations representing rare genetic neurodevelopmental disorders. The foundation joined as a member in April 2021 to pool efforts, studies and data, and accelerate clinical trial readiness. The consortium de-risks therapeutic development by grouping disorders with similar symptoms.
  • RARE-XcoreStrategic or Co-development Partner · 1 March 2021RARE-X is a 501(c)(3) nonprofit data-sharing platform powered by the Broad Institute of MIT and Harvard. The foundation partnered with RARE-X to build a Data Collection Program for the CACNA1A community to accelerate discovery of treatments through patient-owned, structured data collection.
  • National Institute of Neurological Disorders and Stroke (NINDS/NIH)coreStrategic or Co-development Partner · 1 February 2021NINDS, part of the NIH, is the largest funding body for scientific research in the US. The foundation hosts annual Research Roundtables at NINDS facilities, with NINDS grant program managers participating in working groups focused on natural history, variant classification, and preclinical to clinical pathways.
  • Chung Lab at Columbia University / Boston Children's HospitalcoreStrategic or Co-development PartnerDr. Wendy Chung leads the CACNA1A Natural History Study. In July 2023, Dr. Chung joined Boston Children's Hospital as Chief of Pediatrics while maintaining her role leading clinical research at the Simons Foundation. She directs NIH-funded research programs and has authored over 400 peer-reviewed papers. The foundation partnered with her lab to conduct comprehensive natural history data collection.
  • Danny Did FoundationminorGTM or Marketing PartnerReference resource for seizure monitoring devices. The Danny Did Foundation provides grants for seizure monitoring devices, which are recommended safety equipment for CACNA1A patients with epilepsy.
  • NAPA CenterminorGTM or Marketing PartnerNAPA Center is a pediatric therapy center with five US locations (L.A., Denver, Boston, Austin, Chicago) and two in Australia. They offer free online resources and tips for feeding therapies relevant to CACNA1A families dealing with feeding difficulties due to autism, sensory processing deficits, and motor impairments.
  • Disability Rights Legal CenterminorGTM or Marketing PartnerDRLC provides litigation support and advocacy resources for CACNA1A families navigating disability rights issues including school accommodations, healthcare access, and insurance matters. Christopher Knauf serves as Director of Litigation contributing educational content.
  • Simons Foundation / Simons SearchlightminorStrategic or Co-development PartnerDr. Wendy Chung serves as Director of Clinical Research at the Simons Foundation, which runs Simons Searchlight study for neurogenetic conditions. Simons Searchlight serves as a model for data collection approaches.
  • Children's Hospital of Philadelphia (CHOP)minorStrategic or Co-development PartnerDr. Ingo Helbig from CHOP participated in the FDA Patient Listening Session in January 2026. CHOP researchers collaborate on research initiatives and provide clinical expertise.
  • COMBINEDBrain / Dr. Pangkong FoxcoreStrategic or Co-development PartnerDr. Pangkong Fox serves as Science Engagement Director for the foundation and led the CACNA1A Disease Concept Model Study with COMBINEDBrain, identifying key symptoms impacting quality of life.
  • Broad Institute of MIT and HarvardcoreTechnology or IntegrationThe Broad Institute powers the RARE-X data collection platform used by the foundation. It supports patients in data collection and structuring, clinicians in accelerating diagnosis, and researchers with data needed for breakthrough treatments.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

CACNA1A Foundation competitors and assessment

Company assessment

Direct peers

  • RARE-X: 501(c)(3) data-sharing platform powered by the Broad Institute that helps rare disease communities (including CACNA1A) collect, structure, and share patient-owned data. A direct operational and strategic partner of the foundation and a model peer for patient-driven research infrastructure.
  • STXBP1 Foundation: Parent-led 501(c)(3) focused on STXBP1-related disorders, a related rare genetic neurodevelopmental condition. Operates a similar model: natural history study, family registry, research grants, and clinician education. COMBINEDbrain co-member with overlapping scientific network.
  • SYNGAP1 Foundation: Patient-advocacy foundation for SYNGAP1-related neurodevelopmental disorder. Similar parent-led, all-volunteer DNA-driven model with research grants, registry, and FDA engagement; overlapping scientific advisory networks and COMBINEDbrain consortium participation.
  • SCN2A Foundation: Family-driven foundation supporting research and awareness for SCN2A-related disorders, another ion-channel mutation with overlapping ataxia/epilepsy phenotypes. Operates with a similar small-staff, parent-led, research-grant-funding model.
  • COMBINEDbrain: Non-profit consortium of 25 patient-advocacy foundations for rare genetic neurodevelopmental disorders. CACNA1A Foundation is a member; the organizations share clinical-trial readiness infrastructure, natural history approaches, and Disease Concept Model studies for overlapping indications.
  • Dravet Syndrome Foundation: Patient-advocacy foundation for Dravet syndrome (a rare genetic epilepsy). Runs research grant programs, family conferences, and FDA engagement. A more mature peer showing the path from parent-led foundation to clinical-trial pipeline for a CACNA1A-overlapping channelopathy.

Broad incumbents

  • National Organization for Rare Disorders (NORD): Largest US umbrella organization for rare disease patient advocacy. Does not specialize in CACNA1A but provides policy advocacy, research grants, and registry infrastructure that smaller single-disease foundations leverage; a natural policy/umbrella peer.
  • EveryLife Foundation for Rare Diseases: DC-based rare disease policy and advocacy nonprofit focused on federal funding, FDA engagement, and newborn screening. Operates one level above single-disease foundations, including CACNA1A, shaping the regulatory environment they depend on.

Emerging players

  • Simons Searchlight: Research program of the Simons Foundation collecting phenotypic and genetic data for rare neurogenetic conditions (including some overlapping channelopathies). Functions as both a partner and a competing/complementary registry model for CACNA1A natural history efforts.

Others

  • Chan Zuckerberg Initiative — Rare As One Network: CZI's Rare As One program funds a network of rare disease patient-led foundations (including CACNA1A Foundation) to build organizational capacity and accelerate research. Less a peer and more the foundation's primary philanthropic sponsor and peer cohort network.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

CACNA1A Foundation social profiles

Digital presence

CACNA1A Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CACNA1A Foundation leadership team

Management profile

Number of profiles

Profiles3 records

CACNA1A Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CACNA1A Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CACNA1A Foundation

What does CACNA1A Foundation do?

CACNA1A Foundation is a parent-led 501(c)(3) non-profit that funds life-changing research and provides free educational, community, and research-engagement services for individuals and families affected by CACNA1A-related disorders. Its core offerings include the CACNA1A Natural History Study (with the Chung Lab at Columbia University), the RARE-X Data Collection Program, a Research Grant Program, an annual Family & Scientific Conference, a webinar series, a contact registry, and an extensive library of clinician and family resources.

Is CACNA1A Foundation a public or private company?

CACNA1A Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CACNA1A Foundation founded?

CACNA1A Foundation was founded in 2019. It employs 11 to 50 people.

Where is CACNA1A Foundation based?

CACNA1A Foundation is headquartered in Norwalk, United States, in the North America region.

How does CACNA1A Foundation make money?

Two revenue lines are on record. Donations and Fundraising is the primary driver. The others are research and Operating Grants.

Who are CACNA1A Foundation's main competitors?

Direct peers on record are RARE-X, STXBP1 Foundation, SYNGAP1 Foundation, SCN2A Foundation, COMBINEDbrain and Dravet Syndrome Foundation. Broad incumbents are National Organization for Rare Disorders (NORD) and EveryLife Foundation for Rare Diseases. Simons Searchlight is listed as an emerging player. Chan Zuckerberg Initiative — Rare As One Network is listed as an others.

Does CACNA1A Foundation have an API?

No public API is recorded for CACNA1A Foundation.

What industry is CACNA1A Foundation in?

CACNA1A Foundation's product category is Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of HLAJALAB, Health Research Funding Agencies (Public/Quasi-Public). Its NAICS code is 813212 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals